In conclusion, dual targeting of the Aurora A kinase and mTOR resulted in marginal clinical benefit in a population of patients with refractory solid tumors, including a cohort of patients with pancreatic adenocarcinoma. Here, MTOR is linked to pancreatic adenocarcinoma.